Angiogenesis may pose a clinical challenge in glaucoma during the wound healing phase after glaucoma filtration surgery (GFS). In recent years, anti-VEGF antibody bevacizumab (BVZ) has been used in GFS in order to improve the operation success rate safely, such as primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma,chronic angle closure glaucoma, neovascular glaucoma, and the filtering surgery after failure of glaucoma surgery.The mode of application include topical, subconjunctival injection, intracameral injection, intravitreal injection, combination therapy, etc.(Int Rev Ophthalmol, 2017, 41: 323-327)